IP Library Granted Patent US 7,517,659
Granted Patent B2
US 7,517,659 · App. 10/701,013 · Granted Apr 14, 2009

Potassium channel molecules and uses therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,517,659
App. No.
10/701,013
Granted
Apr 14, 2009
Kind
B2
Abstract

The invention provides isolated nucleic acids molecules, designated TWIK nucleic acid molecules, which encode proteins involved in potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TWIK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TWIK gene has been introduced or disrupted. The invention still further provides isolated TWIK proteins, fusion proteins, antigenic peptides and anti-TWIK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Claims (28)

1. A method for identifying a compound which binds to a polypeptide, comprising:

i) contacting a polypeptide selected from the group consisting of:

a) a polypeptide which is at least 95% identical to the amino acid sequence of SEQ ID NO:11;

b) a polypeptide which is at least 95% identical to the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit Number PTA-1640; and

c) a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:10 or SEQ ID NO:12;

with a test compound under conditions suitable for binding; and

ii) detecting binding of the test compound to the polypeptide;

thereby identifying a compound which binds to the polypeptide.

2. The method of claim 1 , wherein the polypeptide further comprises heterologous sequences.

3. The method of claim 1 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) direct detection of test compound/polypeptide binding;

b) a competition binding assay;

c) detecting binding of the test compound to the polypeptide using an antibody; and

d) a yeast two-hybrid assay.

4. A method for identifying a compound which binds to a polypeptide, comprising:

i) contacting a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO:11;

b) a polypeptide comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit Number PTA-1640; and

c) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:10 or SEQ ID NO:12;

with a test compound under conditions suitable for binding; and

ii) detecting binding of the test compound to the polypeptide;

thereby identifying a compound which binds to the polypeptide.

5. The method of claim 4 , wherein the polypeptide further comprises heterologous sequences.

6. The method of claim 4 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) direct detection of test compound/polypeptide binding;

b) a competition binding assay;

c) detecting binding of the test compound to the polypeptide using an antibody; and

d) a yeast two-hybrid assay.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2011
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 026586/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2009
From: MILLENNIUM PHARMACEUTICALS, INC.
To: BAYER SCHERING PHARMA AG
Reel/Frame 022299/0730 →